Compound Evidence File
#EC-2026-0796
Fluoxymesterone (Halotestin) Raw
Filed under Raw Materials. The bureau holds 88 laboratory returns for this compound from 27 distinct subjects. Scores below are per-subject aggregates; open a subject row for the underlying evidence.
Cross-Index
Subjects Shipping This Compound
27 SUBJECTS| Subject | Grade | Samples | Mean | Min | Max | First seen | Last seen |
|---|---|---|---|---|---|---|---|
| Tianjin Finder Chemical TFCCASE #VI-2026-0693 | A | 7 | 10.0 | 9.9 | 10.0 | 14 Nov 2025 | 16 Apr 2026 |
| HomopeptideCASE #VI-2026-0760 | A | 4 | 10.0 | 9.9 | 10.0 | 24 May 2026 | 24 May 2026 |
| Kerui PeptidesCASE #VI-2026-0626 | A | 4 | 10.0 | 9.9 | 10.0 | 3 Jan 2026 | 25 Mar 2026 |
| Hubei JianxiangCASE #VI-2026-0048 | A | 4 | 10.0 | 9.9 | 10.0 | 26 Mar 2026 | 6 Jul 2026 |
| WuXi TIDESCASE #VI-2026-0335 | A | 4 | 10.0 | 9.9 | 10.0 | 8 Dec 2025 | 7 May 2026 |
| JEEP PeptidesCASE #VI-2026-0457 | A | 3 | 10.0 | 9.9 | 10.0 | 6 May 2026 | 20 Jun 2026 |
| Flourishglobal PeptideCASE #VI-2026-0630 | A | 3 | 10.0 | 9.9 | 10.0 | 1 Apr 2026 | 9 Jun 2026 |
| Shanghai Sigma AudleyCASE #VI-2026-0505 | A | 3 | 10.0 | 10.0 | 10.0 | 26 May 2026 | 25 Jun 2026 |
| Sangon BioCASE #VI-2026-0671 | A | 2 | 10.0 | 10.0 | 10.0 | 15 Apr 2026 | 10 Jun 2026 |
| BachemCASE #VI-2026-0314 | A | 2 | 10.0 | 10.0 | 10.0 | 3 Mar 2026 | 1 May 2026 |
| Shanghai ERP BiotechnologyCASE #VI-2026-0936 | A | 4 | 9.9 | 9.9 | 10.0 | 17 Jan 2026 | 5 Jul 2026 |
| Shanghai Wibson BiotechnologyCASE #VI-2026-0379 | A | 4 | 9.9 | 9.9 | 10.0 | 2 Dec 2025 | 7 Jul 2026 |
| Chinese Peptide CompanyCASE #VI-2026-0184 | A | 3 | 9.9 | 9.9 | 9.9 | 13 Jan 2026 | 1 Jun 2026 |
| QYAOBIOCASE #VI-2026-0861 | A | 2 | 9.9 | 9.9 | 10.0 | 8 Mar 2026 | 24 Jun 2026 |
| Mokemei BiotechnologyCASE #VI-2026-0540 | A | 2 | 9.9 | 9.9 | 10.0 | 5 Jun 2026 | 27 Jun 2026 |
| Qingdao Sigma Chemical QSCCASE #VI-2026-0538 | A | 2 | 9.6 | 9.4 | 9.7 | 24 May 2026 | 24 May 2026 |
| Nantong Guangyuan Chemical GYCCASE #VI-2026-0284 | A | 8 | 9.1 | 7.9 | 10.0 | 23 May 2026 | 23 May 2026 |
| Wuhan Wansheng Bio (WWB)CASE #VI-2026-0594 | A | 2 | 9.1 | 8.5 | 9.7 | 24 May 2026 | 24 May 2026 |
| Shanghai Sigma Audley SSACASE #VI-2026-0486 | A | 8 | 8.6 | 7.8 | 9.6 | 24 May 2026 | 24 May 2026 |
| Glbiochem (Shanghai)CASE #VI-2026-0704 | A | 8 | 8.0 | 7.3 | 8.7 | 24 May 2026 | 24 May 2026 |
| Zhang TYCASE #VI-2026-0070 | X | 1 | 7.6 | 7.6 | 7.6 | 2 Apr 2025 | 2 Apr 2025 |
| Chimera PeptidesCASE #VI-2026-0260 | X | 1 | 7.6 | 7.6 | 7.6 | 20 Jun 2025 | 20 Jun 2025 |
| PeptidologyCASE #VI-2026-0520 | X | 1 | 7.0 | 7.0 | 7.0 | 13 Feb 2025 | 13 Feb 2025 |
| Shanghai BaojuCASE #VI-2026-0233 | X | 1 | 6.5 | 6.5 | 6.5 | 21 May 2025 | 21 May 2025 |
| PeptiLab ResearchCASE #VI-2026-0267 | X | 1 | 5.9 | 5.9 | 5.9 | 3 Jun 2025 | 3 Jun 2025 |
| ZZQ PeptidesCASE #VI-2026-0550 | E | 2 | 5.3 | 5.1 | 5.6 | 27 Feb 2025 | 24 May 2026 |
| Peptide GurusCASE #VI-2026-0854 | X | 2 | 3.4 | 1.0 | 5.8 | 2 Apr 2025 | 17 May 2026 |
Open any subject to view the batch-level evidence for Fluoxymesterone (Halotestin) Raw alone.